HilleVax, Inc. and XOMA Royalty Corporation have announced a definitive merger agreement, under which XOMA Royalty will acquire all outstanding shares of HilleVax common stock. The transaction involves a cash payment of $1.95 per share plus a contingent value right. The tender offer to acquire HilleVax shares is expected to commence by August 18, 2025, with the acquisition anticipated to close in September 2025. Approximately 22.9% of HilleVax shareholders, including certain officers, directors, and stockholders, have agreed to support the merger by tendering their shares. The announcement was made by both companies, with Leerink Partners and Latham & Watkins LLP advising HilleVax, and Gibson, Dunn & Crutcher LLP advising XOMA Royalty.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。